MMWR. Morbidity and mortality weekly report
-
MMWR Morb. Mortal. Wkly. Rep. · Nov 2002
Progress toward poliomyelitis eradication--Ethiopia, Somalia, and Sudan, January 2001-October 2002.
Since the World Health Assembly resolved in May 1988 to eradicate poliomyelitis, the estimated number of polio cases globally has declined >99%. The number of countries in which polio was estimated to be endemic decreased from 125 in 1988 to 10 in 2001, and three World Health Organization (WHO) regions (American, European, and Western Pacific) comprising approximately 55% of the world's population have been certified polio-free. ⋯ This report describes intensified polio eradication activities in these countries during January 2001-October 2002, summarizes progress made, and highlights remaining challenges. Continued political commitment and financial support will be required to eradicate polio in these countries.
-
MMWR Morb. Mortal. Wkly. Rep. · Nov 2002
Practice Guideline GuidelineUse of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices.
In December 2000, the Advisory Committee on Immunization Practices (ACIP) released its recommendations for using anthrax vaccine in the United States. Because of recent terrorist attacks involving the intentional exposure of U. ⋯ These recommendations supplement the previous ACIP statement in three areas: use of anthrax vaccine for pre-exposure vaccination in the U. S. civilian population, the prevention of anthrax by postexposure prophylaxis (PEP), and recommendations for additional research related to using antimicrobial agents and anthrax vaccine for preventing anthrax
-
MMWR Morb. Mortal. Wkly. Rep. · Nov 2002
Case ReportsAdverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002.
In June 2001, seven cases of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) (previously called multiple organ system failure) in recipients of 17D-derived yellow fever vaccine (YEL) were reported to the Advisory Committee on Immunization Practices (ACIP). ACIP reviewed the cases, recommended enhanced surveillance for adverse events, and updated the ACIP statement on YEL. This report summarizes the preliminary surveillance findings, including two new suspected cases of YEL-AVD and four suspected cases of YEL-associated neurotropic disease (YEL-AND) (previously called postvaccinal encephalitis). Although YEL remains essential for travelers to areas in which yellow fever (YF) is endemic (Figure), these findings underscore the need for continued enhanced surveillance and timely clinical assessment of YEL-associated disease.